An Open Label, 3-arm, Randomised Phase II Study to Compare the Safety and Efficacy of Ponatinib in Combination With Either Chemotherapy or Blinatumomab With Imatinib Plus Chemotherapy as Front-line Therapy for Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Blinatumomab (Primary) ; Imatinib; Ponatinib
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms EWALL-Ph-03
- 17 May 2021 Status changed from not yet recruiting to recruiting.
- 05 Jan 2021 New trial record